One of the interesting findings revealed in this study is the observation that EphA2 siRNA treatment can significantly attenuate FAK phosphorylation and expression of membrane-bound RhoA in non-metastatic RCC cells but not in metastatic RCC cells, which is consistent with the corresponding results about viability, resistance to apoptosis and invasion after EphA2 siRNA transfection. The gene discussed is PTK2; the disease is renal cell carcinoma.